Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer

Gene Therapy

Volumn 17, Issue 6, 2010, Pages 805-810

  Castelo Branco, P ^a,b,c   Passer, B J ^a,b   Buhrman, J S ^a   Antoszczyk, S ^a,b   Marinelli, M ^a   Zaupa, C ^a,b   Rabkin, S D ^a,b   Martuza, R L ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Cancer therapy; HSV; TRAMP; Virotherapy

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; HERPESVIRUS VECTOR; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; PROTEIN TYROSINE PHOSPHATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; LUNG TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; VIRAL GENE DELIVERY SYSTEM; ANIMAL; C57BL MOUSE; CYTOTOXICITY; GENE TRANSFER; GENETICS; IMMUNIZATION; IMMUNOLOGY; MALE; ONCOLYTIC VIROTHERAPY; PROCEDURES; PROSTATIC NEOPLASMS; SIMPLEXVIRUS; TRANSGENE;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; GENE TRANSFER TECHNIQUES; IMMUNIZATION; MALE; MICE; MICE, INBRED C57BL; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSTATIC NEOPLASMS; PROTEIN TYROSINE PHOSPHATASES; SIMPLEXVIRUS; TRANSGENES;

MUS; SIMPLEXVIRUS;

EID: 77953479211     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.20     Document Type: Article

References (38)

1. Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ. Prostate cancer: the new landscape. Curr Opin Urol 2009; 19: 154-160.
2. Mitchell RE, Chang SS. Current controversies in the treatment of high-risk prostate cancer. Curr Opin Urol 2008; 18: 263-268.
3. Sia M, Rosewall T, Warde P. Radiotherapy as primary treatment modality. Front Radiat Ther Oncol 2008; 41: 15-25.
4. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
5. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
6. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 2002; 9: 967-978.
7. Kuroda T, Martuza RL, Todo T, Rabkin SD. Flip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases. BMC Biotech 2006; 6: 40.
8. Aghi M, Martuza RL. Oncolytic viral therapies\the clinical experience. Oncogene 2005; 24: 7802-7816.
9. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-117.
10. Post DE, Fulci G, Chiocca EA, Van Meir EG. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004; 4: 41-51.
11. Passer BJ, Castelo-Branco P, Buhrman JB, Varghese S, Rabkin SD, Martuza RL. Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells. Cancer Gene Ther 2009; 16: 551-560.
12. Harrington KJ, Melcher A, Vassaux G, Pandha HS, Vile RG. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008; 10: 362-370.
13. Toda M, Rabkin SD, Kojima H, Martuza RL. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999; 10: 385-393.
14. Thomas DL, Fraser NW. HSV-1 therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther 2003; 8: 543-551.
15. Benencia F, Courrèges MC, Conejo-Garć?a JR, Mohamed-Hadley A, Zhang L, Buckanovich RJ et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12: 780-802.
16. Li H, Dutuor A, Tao L, Fu X, Zhang X. Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clin Cancer Res 2007; 13: 316-322. (Pubitemid 46121885)
17. Lin MF, DaVolio J, Garcia-Arenas R. Expression of human prostatic acid phosphatase activity and the growth of prostate carcinoma cells. Cancer Res 1992; 52: 4600-4607.
18. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001; 167: 7150-7156.
19. Ahmad S, Casey G, Sweeney P, Tangney M, O'Sullivan G. Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther 2009; 17: 1101-1108.
20. Gregor PD, Wolchok JD, Turaga V, Latouche JB, Sadelain M, Bacich D et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005; 116: 415-421.
21. Gold JS, Ferrone CR, Guevara-Patiño JA, Hawkins WG, Dyall R, Engelhorn ME et al. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol 2003; 170: 5188-5194.
22. Gallo P, Dharmapuri S, Nuzzo M, Maldini D, Iezzi M, Cavallo F et al. Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 2005; 113: 67-77.
23. Lu Y, Wei Y, Tian L, Zhao X, Yang L, Hu B et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003; 170: 3162-3170.
24. Walker JR, McGeagh KG, Sundaresan P, Jorgensen TJ, Rabkin SD, Martuza RL. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999; 10: 2237-2243.
25. Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers. Cancer Gene Ther 2006; 13: 253-265.
26. Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 2005; 65: 10663-10668.
27. Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL et al. Oncolytic HSV armed with platelet factor 4, an antiangio-genic agent, shows enhanced efficacy. Mol Ther 2006; 14: 789-797.
28. Varghese S, Rabkin SD, Nielsen PG, Wang W, Martuza RL. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 2006; 12: 2919-2927.
29. Aghi M, Visted T, Depinho RA, Chiocca EA. Oncolytic herpes virus with defective ICP6 specifically replicates in quiescent cells with homozygous genetic mutations in p16. Oncogene 2008; 27: 4249-4254.
30. Goldstein DJ, Weller SK. Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant. J Virol 1988; 62: 196-205.
31. Mineta T, Rabkin SD, Martuza RL. Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reduc-tase-deficient herpes simplex viral mutant. Cancer Res 1994; 54: 3963-3966.
32. Fong L, Ruegg CL, Brockstedt D, Engleman EG, Laus R. Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol 1997; 159: 3113-3117.
33. Johnson LE, Frye TP, Chinnasamy N, Chinnasamy D, McNeel DG. Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells. Cancer Immunol Immunother 2007; 56: 885-895.
34. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325-3330.
35. Hall SJ, Mutchnik SE, Chen S-H, Woo SLC, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997; 70: 183-187.
36. Davis L, Kuehl M, Battey J. Basic Methods in Molecular Biology. Appleton & Lange: Norwalk, CT, 1994.
37. Grossmann ME, Wood M, Celis E. Expression, specificity and immunotherapy potential of prostate-associated genes in murine cell lines. World J Urol 2001; 19: 365-370.
38. Vihko P, Virkkunen P, Henttu P, Roiko K, Solin T, Huhtala ML. Molecular cloning and sequence analysis of cDNA encoding human prostatic acid phosphatase. FEBS Lett 1988; 236: 275-281.